Latest Breaking News On - National medical products administration - Page 2 : comparemela.com

Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18 2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

Rhui zhouUnited statesInnovent biologicsHana claudinEli lillyXianjun yuSanofi incyteInnovent or companyNational medical products administrationAmerican society of clinical oncologyGastrointestinal cancers congressInnovent biologics incFudan university shanghai cancer centerPrnewswire innovent biologics incBiliary cancer working groupMd anderson cancer center

GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in

United statesYu wangVanesa gregorcRafael rosellChina national medical products administrationAmerican society of clinical oncologyCandiolo cancer instituteGenfleet therapeuticsClinical oncologyNational medical products administrationChief medical officerPriority review designationBreakthrough therapy designationsThailand business

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Wei liThoracic cancer instituteTongji university school of medicineMedical oncologyShanghai pulmonary hospitalTongji university schoolDrug evaluationNational medical products administration

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
thailand-business-news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thailand-business-news.com Daily Mail and Mail on Sunday newspapers.

Li zhangUnited statesUnited kingdomInternational agency for research on cancerJapan national cancer registryAmerican cancer societySun yat sen university cancer centerAkeso incAmerican society of clinical oncologyNational medical products administrationWorld health organizationShowed clinically meaningfulStatistically significant benefitPatients previously receivingTreatment discontinuationAdverse events

Ivonescimab In Combination With Chemotherapy Approved In China By NMPA For 2L+ Egfrm NSCLC Based On Harmoni-A Clinical Trial: Positive Trend Observed

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0

Prnewswire akeso incNational medical products administrationShowed clinically meaningfulStatistically significant benefitPatients previously receivingAdverse eventsTreatment discontinuationOral presentationManuscript published